Omphalos Secures BARDA Support for Pathogen-Agnostic Antimicrobial Strategy Simulation

Published by Omphalos Lifesciences on December 11, 2025December 11, 2025

We are excited to share that Omphalos Lifesciences Inc has been selected to receive non-dilutive support from Biomedical Advanced Research and Development Authority (BARDA) through MATTER’s Paratus digital health program!

👉 Read the full article on MATTER’s website

This support enables us to advance our 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐦𝐚𝐛𝐥𝐞 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐜𝐞𝐥𝐥 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 by developing next-generation computational models of high-priority, hospital-acquired pathogens. Our work aligns with BARDA’s mission to accelerate new therapeutic strategies for antimicrobial resistance (#AMR) and demonstrates how simulation-driven platforms can reshape infectious disease R&D.

AMR continues to be one of the most urgent global health challenges. A recent global modeling study projects that drug-resistant infections could directly account for about 39 million deaths between 2025 and 2050, highlighting the need for new approaches.

As part of this effort, we are building whole-cell models of 𝑨𝒄𝒊𝒏𝒆𝒕𝒐𝒃𝒂𝒄𝒕𝒆𝒓 𝒃𝒂𝒖𝒎𝒂𝒏𝒏𝒊𝒊 in drug-susceptible and multidrug-resistant forms, supported by a generalized microbial modeling framework. The prototype models and the accompanying software infrastructure are planned for deployment in Q1 2026.

Our goal is to provide simulation-driven AI tools that help researchers and therapeutic developers evaluate candidate drugs against likely resistance scenarios early in the development process, creating a more predictive and resilient pipeline for antimicrobial innovation.

We look forward to sharing our progress as this work advances.

#AntimicrobialResistance #DigitalBiology #Biotech #DrugDiscovery #InfectiousDiseases #VirtualCell #LifeScience